Soleno Therapeutics Faces Class Action Lawsuit Over DCCR Safety and Efficacy Concerns

### Legal Troubles for Soleno Therapeutics: Safety and Efficacy Concerns Emerge

Soleno Therapeutics Inc. faces significant legal challenges as a class action lawsuit is initiated on behalf of investors who purchased the company’s stocks between March 26, 2025, and November 4, 2025. The legal action, primarily driven by alleged violations of federal securities laws, arises following disappointing clinical results for Soleno's product, DCCR (marketed as VYKAT™ XR), which is intended for treating hyperphagia associated with Prader-Willi Syndrome. The situation escalates after a report on November 5, 2025, led to a staggering 26% drop in the company’s stock price, illuminating investor concerns over the drug's safety profile and overall market viability.

Central to the allegations are claims that Soleno significantly downplayed safety issues linked to DCCR. The lawsuit details that participants in Soleno's clinical trials experienced adverse effects, including dangerous fluid retention, which the company allegedly failed to adequately disclose. Critics argue that the reported clinical results overstated the drug's efficacy and commercial potential, thus misleading investors about the true risks involved. This misrepresentation could have long-lasting implications not only on Soleno's market performance but also on the trust it holds within the pharmaceutical industry.

The lawsuit gains additional momentum following claims from activist short seller Scorpion Capital, who raised alarms about Soleno's disclosures in August 2025. They reported a disturbing uptick in hospitalizations for potential heart failure among children treated with DCCR, causing significant public concern. This scrutiny suggests that the drug's introduction into the market might be precarious, as growing adverse reports could threaten not only future prescriptions but also the company’s reputation amongst healthcare providers. As the legal situation develops, Soleno must navigate the ramifications of these allegations while striving to reassure stakeholders about the integrity and safety of its product.

In parallel to this troubling scenario, multiple law firms are mobilizing to conduct investigations and file class action lawsuits against Soleno Therapeutics. Hagens Berman, Schall Law Firm, DJS Law Group, and Levi & Korsinsky, LLP are actively reaching out to potentially affected investors to discuss their rights and options leading up to the May 5, 2026, deadline for lead plaintiff status. As these proceedings unfold, the emphasis remains firmly on addressing the potential impact of the safety concerns raised regarding DCCR, marking a pivotal moment for the company as it seeks to navigate turbulent legal waters and restore confidence amongst investors and healthcare professionals alike.

Affected investors are strongly encouraged to engage with these law firms for more information on their claims. As Soleno Therapeutics confronts these challenges, the focus increasingly shifts to the accountability measures and the future direction of its product offerings in an already complex and competitive therapeutic landscape.